The landscape of immune checkpoint inhibitor therapy in advanced lung cancer

BACKGROUND: The advent of immune checkpoint inhibitors (ICIs) therapy has resulted in significant survival benefits in patients with non-small-cell lung cancer (NSCLC) without increasing toxicity. However, the utilisation of immunotherapy for small-cell lung cancer (SCLC) remains unclear, with a sca...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chengdi, Li, Jingwei, Zhang, Qiran, Wu, Jiayang, Xiao, Yuxuan, Song, Lujia, Gong, Hanlin, Li, Yalun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403352/
https://www.ncbi.nlm.nih.gov/pubmed/34454455
http://dx.doi.org/10.1186/s12885-021-08662-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403352/
https://www.ncbi.nlm.nih.gov/pubmed/34454455
http://dx.doi.org/10.1186/s12885-021-08662-2

Ejemplares similares